Any feedback?
Literature summary for 3.1.1.2 extracted from
- Paraoxonase 1 activities and polymorphisms in autism spectrum disorders (2010), J. Cell. Mol. Med., 14, 600-607.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | both PON1 bioavailability and catalytic activity are decreased in children with autism spectrum disorders | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| blood plasma | - |
Homo sapiens | - |
Specific Activity [micromol/min/mg]
| Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
|---|---|---|---|
| 85.05 | - |
using phenyl acetate as substrate (arylesterase activity of PON1), at 25°C | Homo sapiens |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| additional information | PON1 catalyses the hydrolysis of arylesters, toxic organophosphate compounds, carbamates and lactones, shows higher arylesterase than paraoxonase activity | Homo sapiens | ? | - |
? |  |
| phenyl acetate + H2O | - |
Homo sapiens | phenol + acetate | - |
? | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
